Boston Scientific hit with $42M verdict in drug-eluting stents IP case

[Image from Pixabay]Boston Scientific (NYSE:BSX) must pay $42 million in unpaid royalties to TissueGen and the University of Texas, a federal jury in Delaware has ruled.

The jury verdict yesterday came after the finding that Boston Scientific’s Synergy BP drug-eluting stents infringed on TissueGen and the university’s IP.

The patent under question arose out of research that TissueGen co-founder Kevin Nelson, PhD, conducted at the University of Texas Arlington in the late 1990s. Filed in 2000, the patent was for a “drug-releasing biodegradable fiber implant.”

The amended lawsuit complaint explained how Nelson came up with the idea:

“Though the industry believed otherwise, Dr. Nelson believed in the commercial viability of a drug-eluting stent based on biodegradable polymer fibers capable of controlled release of sensitive therapeutics. Dr. Nelson came up with the idea for his drug-eluting stent innovation while investigating wa…

Read more
  • 0